G1 Therapeutics Inc
Change company Symbol lookup
Select an option...
GTHX G1 Therapeutics Inc
$RFTREES Refinitiv Eurozone ESG Select Index
NEMCF New Energy Metals Corp
SLCT Select Bancorp Inc
HPQ HP Inc
GOLD Barrick Gold Corp
DGNR Dragoneer Growth Opportunities Corp
EQMEF Equity Metals Corp
TS Tenaris SA
TRXC Transenterix Inc
Go

Health Care : Biotechnology | Small Cap Blend
Company profile

G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6. Trilaciclib and G1T38 are designed to be combined and enhance the anti-tumor activity of current therapies. It is also developing G1T48, an oral selective estrogen receptor degrader (SERD) for the treatment of breast cancer. The Company is evaluating trilaciclib in three Phase II clinical trials. G1T38 is being evaluated in combination with Faslodex in a Phase I b/II a trial for patients with estrogen receptor-positive, HER2-negative breast cancer.

Price
Delayed
$21.53
Day's Change
-0.16 (-0.74%)
Bid
--
Ask
--
B/A Size
--
Day's High
21.80
Day's Low
21.20
Volume
(Light)

Today's volume of 205,570 shares is on pace to be much lighter than GTHX's 10-day average volume of 1,201,515 shares.

205,570

Unable to locate that news article. Back to news results

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.